Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare topic
No spam. Unsubscribe anytime.
Pharmacy, drugs and device package draws legal and policy pushback during Senate debate
Summary
Senate consideration of the pharmaceutical and device package (house committee substitute for senate substitute for senate committee substitute for senate bill 878) provoked sustained discussion about constitutional procedural constraints, insurance mandates and legal risk; senators urged caution and some called for conference instead of immediate passage.
A broad package covering pharmacy duties, pharmaceutical drugs and devices — identified on the floor as the house committee substitute for Senate substitute for Senate committee substitute for Senate Bill 878 — prompted lengthy floor debate on May 11 over scope, title changes and potential legal exposure.
On the floor the senator advancing the adoption explained the bill includes provisions on meth-precursor/pseudoephedrine tracking, non-opioid medication access, blood-pressure monitoring devices for pregnant and postpartum women, and other durable medical equipment provisions that the House had added. "The house also added another provision... to allow patients to have access to non-opioid medication under their plans as an alternative to opioids," the sponsor said while describing the package.
Several senators cautioned that bundling disparate healthcare mandates into one bill could invite Article III, Section 21 legal challenges over germaneness and severability. One senator with legal background outlined the 3-part judicial test — original purpose, comparison to current version and severability — and warned that added mandates might place the whole measure at risk in court. "I do think that those are appropriately raised, and I do think that it is likely that they will sustain court challenges," one senator said.
Despite the concerns, the Senate moved to adopt the house committee substitute and subsequently passed the measure (journal entries record final passage with the constitutional majority noted). Sponsors and several colleagues said they had worked to limit problematic provisions and negotiated some language; others suggested the measure might be better resolved in conference committee to remove controversial mandates before final passage.
Why it matters: the package touches insurance design, pharmacy practice, and patient access to non-opioid alternatives — areas with both clinical and cost implications. Floor debate focused on legal defensibility, potential increases in coverage mandates and the risk that an expansive bill title could invite an all-or-nothing judicial outcome.
